drug · protein
survodutide
Phase 3updated 6mo agoby Boehringer Ingelheim International GmbH🔗 ChEMBL
Phase 3community read0 votes
Protein drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.
targets
Glucagon-like peptide 1 receptorGlucagon receptor
all catalysts(0)
nothing on the calendar yet
Trials studying survodutide
- phase3ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
- phase3SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
- phase3LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- phase3A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
- phase3A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- phase1A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector
- phase3LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- phase3A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
News(10)
- Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked NovemberNovartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…biospace · 6d ago
- Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage testThe Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk f…biospace · 8d ago
- #AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be trickyBoehringer Ingelheim will seek approval for its incretin shot survodutide for obesity next year, after a trial showed that the drug doesn’t increase patients’ risk of cardiovascular events like hea…endpoints · 8d ago
- AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio testBoehringer Ingelheim is gearing up to take survodutide to regulators next year after the obesity drug proved its cardiovascular credentials in its latest phase 3 study.fiercebiotech · 12d ago
- Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugsObesity-focused Zealand Pharma is buying into Generate:Biomedicines’s generative AI platform to create new multispecific drug candidates.biospace · 1mo ago
- Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbersFor the second time in a week, Zealand Pharma’s weight loss pipeline has delivered mixed results, this time in a Phase 2 trial for the Roche-partnered asset petrelintide.biospace · 1mo ago
- 3 takeaways from a European obesity scientific meetingEli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…biopharma_dive · 1mo ago
- Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—againDespite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by c…biospace · 1mo ago
- Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary endpoints. Yet, with the readout echoing earlier data that underwhelmed analy…fiercebiotech · 1mo ago
- Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionAs the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.fiercebiotech · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that